|
May 9
|
How Neurocrine Is Stacking Up Wins In 2024 — And Outperforming Peers
|
|
May 9
|
Neurocrine Biosciences Presents CAHtalyst™ Adult Study Baseline Characteristics and Data on Impact of Supraphysiologic Glucocorticoid Therapy at AACE 2024
|
|
May 9
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1076986 in Healthy Adults
|
|
May 8
|
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1117567 in Healthy Adults
|
|
May 7
|
Neurocrine Biosciences to Present at the BofA Securities 2024 Health Care Conference
|
|
May 7
|
Neurocrine Biosciences to Present Phase 3 Baseline Characteristics Data from the CAHtalyst™ Program of Crinecerfont in CAH, and Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH Studies at ECE 2024
|
|
May 6
|
Neurocrine Biosciences Supports Tardive Dyskinesia Awareness Week by Advocating for Routine Screening and Monitoring
|
|
May 4
|
Nvidia Leads Five Stocks Near Buy Points As Market Rally Picks Up Steam
|
|
May 3
|
Neurocrine Biosciences Presented CAHtalyst™ Pediatric Study Baseline Characteristics and CAHtalog™ Registry Data at PES 2024
|
|
May 2
|
Neurocrine Biosciences First Quarter 2024 Earnings: EPS Misses Expectations
|
|
May 2
|
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings Call Transcript Highlights: Robust Growth ...
|
|
May 2
|
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
|
|
May 2
|
Q1 2024 Neurocrine Biosciences Inc Earnings Call
|
|
May 2
|
Neurocrine Biosciences Inc (NBIX) Q1 2024 Earnings: Strong Revenue Growth and Strategic Advancements
|
|
May 1
|
Why Things Are Looking Up For IBD Stock Of The Day Neurocrine, A Top 1% Biotech
|
|
May 1
|
Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say
|
|
May 1
|
Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates
|
|
May 1
|
Neurocrine Biosciences Reports First Quarter 2024 Financial Results
|
|
Apr 30
|
UPDATE 1-Neurocrine Biosciences' Huntington's disease drug gets FDA approval
|
|
Apr 30
|
Neurocrine Biosciences Announces U.S. FDA Approval of INGREZZA® SPRINKLE (valbenazine) Capsules
|